SC
SRPT icon

Samlyn Capital’s Sarepta Therapeutics SRPT Stock Holding History

Samlyn Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-247,664
Closed -$30M – 113
2023
Q3 		$30M Buy
247,664
+53,283
+27% +$6.02M 0.49% 66
2023
Q2 		$22.3M Buy
+194,381
New +$25.1M 0.38% 61
2017
Q4 		– Sell
-137,867
Closed -$6.25M – 153
2017
Q3 		$6.25M Sell
137,867
-23,433
-15% -$937K 0.16% 100
2017
Q2 		$5.44M Sell
161,300
-73,000
-31% -$2.38M 0.13% 96
2017
Q1 		$6.93M Buy
+234,300
New +$7.25M 0.16% 109

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Samlyn Capital's SRPT Position: Q4 2023 in Review

Samlyn Capital sold out of Sarepta Therapeutics (SRPT) in Q4 2023, closing a stake of 247,664 shares — an estimated $30M sold.

Samlyn Capital first reported a position in SRPT in Q1 2017 and held it in 5 quarters. The position peaked at $30M in Q3 2023. 396 funds tracked by Wall St. Rank hold SRPT as of Q4 2023.

  • Samlyn Capital reported no remaining Sarepta Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Samlyn Capital sold 247,664 Sarepta Therapeutics shares in Q4 2023, an estimated $30M.
  • Samlyn Capital first reported a position in Sarepta Therapeutics in Q1 2017 and held it in 5 quarters.
  • Samlyn Capital's Sarepta Therapeutics position peaked at $30M in Q3 2023.
  • 396 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2023.

Based on Samlyn Capital's 13F filing for Q4 2023, filed 14 Feb 2024.